Bristol-Myers Squibb Company (BMY) traded within a range of $55.3 to $56.11 after opening the day at $55.69. The company has seen its stock decrease in value by -17.16% so far this year. The stock was up close to 0.29% on light volume in last trading session and closed at $55.96 per share. After the recent gain, the stock is currently holding -26.93% below its 52 week high of $77.12 and 14.13% above its 12-month low of $49.03. The shares are down by over 0% in the last three months, and the RSI indicator value of 54.57 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Gilead Sciences Inc. (GILD) continued its downward trend with the stock declining -0.58% or $-0.42 to close the day at $72.42 on light trading volume of 9.22M shares, compared to its three month average trading volume of 9.58M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -27.07%, compared to the industry which has dropped -4.15% over the same period. With RSI of 36.59, the stock should still continue to rise and get closer to its one year target estimate of $95.74, making it a hold for now.
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Hilton Worldwide Holdings Inc. (HLT) gained $0.05 to close the day at a new closing price of $25.26, a 0.2% increase in value from its previous closing price that moved the stock 58.27% above its 52 week low of $16.16. A total of 9.19M shares exchanged hands during the day compared with its three month average trading volume of 7.61M. The stock, which fluctuated between $25.11 and $25.37 during the day, currently situated -0.75% below its 52 week high. The stock is up by 13.62% in the past one month and up by 6.73% over the past three months. With a one year target estimate of $25.95 and RSI of 71.59, the stock still has upside potential, making it a sell for now.
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates through three segments: Ownership, Management and Franchise, and Timeshare. It also licenses its brands to franchisees; provides hotel management services for third parties; and markets and sells timeshare interests owned by Hilton and third parties. In addition, the company provides consumer financing, which includes interest income generated from the origination of consumer loans to finance their purchase of timeshare intervals. It operates hotels under the Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Hilton Hotels & Resorts, Curio – A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Tru by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton, Hilton Grand Vacations, and Hampton Inn brands. As of November 10, 2016, the company had approximately 4,800 managed, franchised, owned, and leased hotels, resorts, and timeshare properties comprising 789,000 rooms in 104 countries and territories. Hilton Worldwide Holdings Inc. was founded in 1919 and is headquartered in McLean, Virginia.